Skip to content

Eos partners with US-based Kineticos to invest over £10M in early-stage Scottish life sciences startups


St Andrews-based investment firm Eos Advisory has entered into a strategic partnership with US-based Kineticos Life Sciences to co-invest in early-stage Scottish life sciences companies.

The venture partnership aims to invest over £10 million over the next five years in oncology-focused life sciences ventures founded in Scotland. Headquartered in Raleigh, North Carolina, Kineticos has a biotech advisory practice and a related fund, the Kineticos Disruptor Fund, to invest in the advancement and commercialisation of clinical research.

As part of the deal, Eos will engage with Scottish Enterprise and a range of other private and public investors to leverage its co-investments. Specifically, the partnership will seek out Scottish-based investment opportunities that address large, unmet medical needs in oncology, neurosciences and rare diseases, new approaches to gene and cell therapies, and precision medicine technologies.

Kevin Grainger, Founder and Chairman of Eos Advisory, said: “This strategic transatlantic partnership between Eos and Kineticos will help find and fund breakthrough ideas from Scotland’s brightest life science entrepreneurs. In addition to the £10 million, Eos and Kineticos have committed, we will leverage additional equity capital from private, institutional and public sources to maximise the impact of these nascent oncology businesses. This funding, along with the commercial expertise of the Eos and Kineticos teams, will accelerate high skill R&D job creation in Scotland and subsequent commercial opportunities in the US which we hope will have a significant impact on improving the early diagnosis and treatment of cancer globally.”

Shailesh Maingi, Founder and Chairman of Kineticos, said: “The Kineticos Disruptor Fund’s mission is simple: to find cures for difficult to treat cancers and rare diseases. The fund invests in cutting edge technology such as Cell and Gene Therapy (CGT), emanating from the world’s leading research scientists and universities. Scotland presents a unique opportunity with its rich history in life sciences innovation and entrepreneurial culture. With our partnership with the excellent Eos team, we hope to build upon the success of Scotland’s eco-system and create a new path for collaboration between leading scientists in Scotland and the United States.”

Mark Bamforth, an investor in the Kineticos Disruptor Fund, said “As a Scot, I am delighted to support this partnership which will help to fund and mentor Scottish companies to support their development and global growth.”

Founded in 2014, Eos has a portfolio of 13 investee companies including Cumulus Oncology, ILC Therapeutics, and Clinspec DX. Eos invests in four key impact areas: disease diagnosis, prevention and treatment; energy security, climate change and pollution; food and water security, and; sustainability of industrial processes and infrastructure.

Founded in 2007, Kineticos is an award-winning organisation supporting Bio-pharmaceutical and Precision Medicine firms. The advisory business provides strategy, licensing, and market access support. The Kineticos Disruptor Fund has invested in cutting edge companies such as Amylyx, Arranta Bio, Brammer Bio and Promaxo. Additionally, the Kineticos Disruptor Fund formed and operates two new CGT biotechs, Inceptor Bio and FastBack Bio